PGx for Cardiology

PGx testing helps cardiology teams personalize treatment by identifying genetic differences that can affect how a patient metabolizes and responds to medications.

The AccessDx PGx Profile:

  • Improves antiplatelet therapy selection
  • Helps prevent serious cardiovascular complications or recurrent cardiac events
  • Helps identify risk for statin intolerance
  • Improves medication effectiveness

Fill out this form to learn more details about PGx use in cardiology practices.

Name
By filling out this form, you agree to receive communications like newsletters, marketing or promotional materials, and other information from AccessDx Laboratory and our parent company, Aranscia®. You may opt-out of receiving communications from us by using the unsubscribe link at the bottom of all emails or contacting us directly.

Cardiology medications consistently rank among the top prescribed drug classes, and many carry actionable pharmacogenomic guidance that can enhance patient safety and treatment efficacy.2

62% of former statin users discontinued their medications due to side effects
Patients whose medications do not match their genetic profile are 30% more likely to be readmitted to the hospital in 90 days
Mutli-gene testing can improve cardiology therapy for 1 in 6 patients beyond antiplatelet treatment alone

Testing Offerings:

PGx Profile – Comprehensive Panel

Includes 37+ high-evidence and emerging-evidence genes, with four add-on genes available (APOE and HLA risk alleles)

PGx Profile – Focused Panel

Includes 20 high-evidence genes with actionable guidance, including HLA risk alleles

Medicine Classes Impacted:

Angiotensin II Receptor Bockers (ARBs)
Angiotensin-Converting Enzyme (ACE) Inhibitors
Antiarrhythmics
Beta-Blockers

Dyslipidemia: Cholesterol Absorption Inhibitor
Dyslipidemia: Fibrates
Dyslipidemia: HMG-CoA Reductase Inhibitors

Inotropic Agents
Loop Diuretics
Other Cardiac Drugs

PGx Use in Cardiology Resources:

      1. Tang, Borui et al. “Genotype-Guided Antiplatelet Therapy Versus Standard Therapy for Patients with Coronary Artery Disease: An Updated Systematic Review and Meta-Analysis.” Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques vol. 25 (2022): 9-23. doi:10.18433/jpps32140
      2. Centers for Disease Control and Prevention. “Prescription Drug Use in the United States, 2015–2016.” NCHS Data Brief, no. 334, 2019, https://www.cdc.gov/nchs/products/databriefs/db334.htm. Accessed 8 Apr. 2025.
      3. Nguyen, Khoa A et al. “A comprehensive review and meta-analysis of risk factors for statin-induced myopathy.” European journal of clinical pharmacology vol. 74,9 (2018): 1099-1109.
        doi:10.1007/s00228-018-2482-9
      4. David, Sean P et al. “The Contribution of Pharmacogenetic Drug Interactions to 90-Day Hospital Readmissions: Preliminary Results from a Real-World Healthcare System.” Journal of personalized medicine vol. 11,12 1242. 23 Nov. 2021, doi:10.3390/jpm11121242
      5. Black, Rachel M et al. “Projected impact of pharmacogenomic testing on medications beyond antiplatelet therapy in percutaneous coronary intervention patients.” Pharmacogenomics vol. 21,7 (2020): 431-441. doi:10.2217/pgs-2019-0185